Skip to main content
. 2018 Sep 9;49(4):463–471. doi: 10.1111/ejn.14109

Figure 2.

Figure 2

Schematic drawing illustrating the evolution of the different sources of cells used for replacement therapy in PD, starting with dopaminergic (DA) progenitors originating from fetal ventral midbrain (fVM), moving on to human pluripotent stem cells (ESCs/iPSCs), and eventually to the development of DA progenitor directly reprogrammed from somatic cells such as skin fibroblasts